Amneal CEO: Changes At Teva, Sandoz And Viatris Give Us Room To Grow
Chirag Patel Talks International Expansion And Focus On Complex Generics
Amid upheaval for leading industry players Sandoz, Teva and Viatris, Amneal sees room to grow both in its home market and internationally, according to co-CEO Chirag Patel.
You may also be interested in...
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
Ahead of revealing its full first-quarter results, Amneal has released limited preliminary details of its financials for the first three months of 2023, pointing to double-digit sales and profit growth in Q1.
Looking back over the first quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from January to March that include the launch of the first US Humira biosimilar, new leadership at the top of some of the industry’s biggest players, annual results and strategy updates, and multiple major industry conferences – as well as the launch of our annual awards.